Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
Hoth’s HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers
NEW YORK, Feb. 26, 2024 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth’s sponsored scientific research conducted at NC State University. The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.